Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Grinyó J[au]:

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Campistol JM et al. Nefrologia. (2015)

Belatacept and Long-Term Outcomes in Kidney Transplantation. Vincenti F et al. N Engl J Med. (2016)

Reduced exposure to calcineurin inhibitors in renal transplantation. Ekberg H et al. N Engl J Med. (2007)

Search results

Items: 1 to 50 of 334

1.

Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis.

Luque A, Serrano I, Ripoll E, Malta C, Gomà M, Blom AM, Grinyó JM, Rodríguez de Córdoba S, Torras J, Aran JM.

Kidney Int. 2019 Nov 6. pii: S0085-2538(19)31049-X. doi: 10.1016/j.kint.2019.10.016. [Epub ahead of print]

PMID:
31982108
2.

Anonymity of organ donors under discussion.

Oliver E, Moreno G, Grinyo JM.

G Ital Nefrol. 2019 Dec 9;36(6). pii: 2019-vol6.

3.

Validation and evaluation of four sample preparation methods for the quantification of intracellular tacrolimus in peripheral blood mononuclear cells by UHPLC-MS/MS.

van Merendonk LN, Fontova P, Rigo-Bonnin R, Colom H, Vidal-Alabró A, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N.

Clin Chim Acta. 2019 Nov 30. pii: S0009-8981(19)32155-2. doi: 10.1016/j.cca.2019.11.033. [Epub ahead of print]

PMID:
31794770
4.

Measurement of calcineurin activity in peripheral blood mononuclear cells by ultra-high performance liquid chromatography-tandem mass spectrometry. Renal transplant recipients application (pharmacodynamic monitoring).

Fontova P, Rigo-Bonnin R, Vidal-Alabró A, Cerezo G, Bestard O, Cruzado JM, Torras J, Grinyó JM, Lloberas N.

Clin Chim Acta. 2019 Aug;495:287-293. doi: 10.1016/j.cca.2019.04.079. Epub 2019 Apr 27.

PMID:
31039337
5.

Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.

Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH; C10-002 Study Group.

Am J Transplant. 2019 Oct;19(10):2865-2875. doi: 10.1111/ajt.15397. Epub 2019 May 24.

PMID:
31012541
6.

siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice.

Narváez A, Guiteras R, Sola A, Manonelles A, Morote J, Torras J, Grinyó JM, Cruzado JM.

PLoS One. 2019 Apr 12;14(4):e0215232. doi: 10.1371/journal.pone.0215232. eCollection 2019.

7.

Refinement of humoral rejection effector mechanisms to identify specific pathogenic histological lesions with different graft outcomes.

Bestard O, Grinyó J.

Am J Transplant. 2019 Mar;19(3):952-953. doi: 10.1111/ajt.15171. Epub 2018 Dec 10. No abstract available.

PMID:
30411840
8.

Reproduction, energy storage and metabolic requirements in a mesophotic population of the gorgonian Paramuricea macrospina.

Grinyó J, Viladrich N, Díaz D, Muñoz A, Mallol S, Salazar J, Castillo R, Gili JM, Gori A.

PLoS One. 2018 Sep 26;13(9):e0203308. doi: 10.1371/journal.pone.0203308. eCollection 2018.

9.

CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.

Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, Cruzado JM, Luque S, Gil-Vernet S, Grinyó JM, Bestard O.

Transplantation. 2018 Nov;102(11):e472-e480. doi: 10.1097/TP.0000000000002421.

PMID:
30130330
10.

Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.

Luque S, Lúcia M, Melilli E, Lefaucheur C, Crespo M, Loupy A, Bernal-Casas D, Gomà M, Jarque M, Crespo E, Montero N, Manonelles A, Cruzado JM, Gil-Vernet S, Grinyó JM, Bestard O.

Am J Transplant. 2019 Feb;19(2):368-380. doi: 10.1111/ajt.15055. Epub 2018 Sep 17.

11.

A multicolour HLA-specific B-cell FluoroSpot assay to functionally track circulating HLA-specific memory B cells.

Luque S, Lúcia M, Crespo E, Jarque M, Grinyó JM, Bestard O.

J Immunol Methods. 2018 Nov;462:23-33. doi: 10.1016/j.jim.2018.07.011. Epub 2018 Jul 31.

PMID:
30075182
12.

Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome.

Meneghini M, Melilli E, Martorell J, Revuelta I, Rigol-Monzó E, Manonelles A, Montero N, Cucchiari D, Diekmann F, Cruzado JM, Gil-Vernet S, Grinyó JM, Bestard O.

Kidney Int Rep. 2018 Mar 30;3(4):926-938. doi: 10.1016/j.ekir.2018.03.015. eCollection 2018 Jul. Erratum in: Kidney Int Rep. 2019 Mar 04;4(4):634.

13.

Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?

Melilli E, Manonelles A, Montero N, Grinyo J, Martinez-Castelao A, Bestard O, Cruzado J.

Clin Kidney J. 2018 Jun;11(3):413-421. doi: 10.1093/ckj/sfx120. Epub 2017 Nov 23.

14.

ANRIL as a genetic marker for cardiovascular events in renal transplant patients - an observational follow-up cohort study.

Arbiol-Roca A, Padró-Miquel A, Vidal-Alabró A, Hueso M, Fontova P, Bestard O, Rama I, Torras J, Grinyó JM, Alía-Ramos P, Cruzado JM, Lloberas N.

Transpl Int. 2018 May 2. doi: 10.1111/tri.13276. [Epub ahead of print]

15.

Long-term changes in the planktonic cnidarian community in a mesoscale area of the NW Mediterranean.

Guerrero E, Gili JM, Grinyó J, Raya V, Sabatés A.

PLoS One. 2018 May 1;13(5):e0196431. doi: 10.1371/journal.pone.0196431. eCollection 2018.

16.

The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?

de Ramon L, Guiteras J, Guiteras R, Cruzado JM, Grinyó JM, Torras J.

Int J Mol Sci. 2018 Apr 25;19(5). pii: E1283. doi: 10.3390/ijms19051283. Review.

17.

Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype.

Lloberas N, Hesselink DA, van Schaik RH, Grinyò JM, Colom H, Gelder TV, Elens L.

Pharmacogenomics. 2018 Mar;19(4):305-310. doi: 10.2217/pgs-2017-0301. Epub 2018 Feb 22.

PMID:
29469606
18.

Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.

Colom H, Andreu F, van Gelder T, Hesselink DA, de Winter BCM, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N.

Clin Pharmacokinet. 2018 Jul;57(7):877-893. doi: 10.1007/s40262-017-0603-8.

PMID:
29159710
19.

Macrophage Overexpressing NGAL Ameliorated Kidney Fibrosis in the UUO Mice Model.

Guiteras R, Sola A, Flaquer M, Hotter G, Torras J, Grinyó JM, Cruzado JM.

Cell Physiol Biochem. 2017;42(5):1945-1960. doi: 10.1159/000479835. Epub 2017 Aug 9.

20.

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.

Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.

21.

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.

Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM.

Pharmacogenet Genomics. 2017 Sep;27(9):313-322. doi: 10.1097/FPC.0000000000000296.

PMID:
28704257
22.

Corrigendum to 'Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients' [Clinica Chimica Acta (2017) 61-67].

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Clin Chim Acta. 2017 Aug;471:94. doi: 10.1016/j.cca.2017.05.024. Epub 2017 May 24. No abstract available.

PMID:
28550742
23.

Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.

Crespo E, Fernandez L, Lúcia M, Melilli E, Lauzurica R, Penin RM, Quer A, Luque S, Quero M, Manonelles A, Torras J, Cruzado JM, Cañas L, Grinyó JM, Bestard O.

Transplantation. 2017 Sep;101(9):2102-2110. doi: 10.1097/TP.0000000000001759.

PMID:
28403126
24.

Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.

Crespo E, Cravedi P, Martorell J, Luque S, Melilli E, Cruzado JM, Jarque M, Meneghini M, Manonelles A, Donadei C, Lloberas N, Gomà M, Grinyó JM, Heeger P, Bestard O.

Kidney Int. 2017 Jul;92(1):201-213. doi: 10.1016/j.kint.2016.12.024. Epub 2017 Mar 6.

25.

Data on genotypic distribution and linkage disequilibrium of several ANRIL polymorphisms in hemodialysis patients.

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Data Brief. 2017 Feb 12;11:221-224. doi: 10.1016/j.dib.2017.02.011. eCollection 2017 Apr.

26.

The Timing of Immunomodulation Induced by Mesenchymal Stromal Cells Determines the Outcome of the Graft in Experimental Renal Allotransplantation.

Merino A, Ripoll E, de Ramon L, Bolaños N, Goma M, Bestard O, Lloberas N, Grinyo JM, Ambròs JT.

Cell Transplant. 2017 Jun 9;26(6):1017-1030. doi: 10.3727/096368917X695010. Epub 2017 Feb 3.

27.

Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M.

Transplantation. 2017 Feb;101 Suppl 2S:S1-S41. doi: 10.1097/TP.0000000000001563. No abstract available.

PMID:
28125449
28.

Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients.

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Clin Chim Acta. 2017 Mar;466:61-67. doi: 10.1016/j.cca.2016.12.029. Epub 2017 Jan 2. Erratum in: Clin Chim Acta. 2017 Aug;471:94.

PMID:
28057453
29.

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N.

Clin Pharmacokinet. 2017 Aug;56(8):963-975. doi: 10.1007/s40262-016-0491-3.

PMID:
28050888
30.

Complete Regression of Psoriatic Arthritis After Belatacept Conversion in a Highly HLA-Sensitized Kidney Transplant Patient.

Meneghini M, Gómez C, Mast R, Melilli E, Grinyó JM, Bestard O.

Am J Transplant. 2017 May;17(5):1409-1413. doi: 10.1111/ajt.14172. Epub 2017 Jan 24.

31.

Datasets for the validation of the "in vivo" siRNA-silencing of CD40 and for the detection of new markers of atherosclerosis progression in ApoE-deficient mice.

Hueso M, De Ramon L, Navarro E, Ripoll E, Cruzado JM, Grinyo JM, Torras J.

Data Brief. 2016 Nov 19;9:1105-1112. eCollection 2016 Dec.

32.

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.

Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.

Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.

33.

Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.

Hueso M, De Ramon L, Navarro E, Ripoll E, Cruzado JM, Grinyo JM, Torras J.

Atherosclerosis. 2016 Dec;255:80-89. doi: 10.1016/j.atherosclerosis.2016.11.002. Epub 2016 Nov 2.

PMID:
27835742
34.

RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets.

de Ramon L, Jarque M, Ripoll E, Bestard O, Grinyo JM, Torras J.

Curr Pharm Des. 2016;22(30):4651-4657. Review.

PMID:
27510493
35.

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.

Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.

36.

Online Haemodiafiltration Improves Inflammatory State in Dialysis Patients: A Longitudinal Study.

Rama I, Llaudó I, Fontova P, Cerezo G, Soto C, Javierre C, Hueso M, Montero N, Martínez-Castelao A, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

PLoS One. 2016 Oct 26;11(10):e0164969. doi: 10.1371/journal.pone.0164969. eCollection 2016.

37.

Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies.

Ortiz F, Gelpi R, Helanterä I, Melilli E, Honkanen E, Bestard O, Grinyo JM, Cruzado JM.

PLoS One. 2016 Aug 17;11(8):e0159717. doi: 10.1371/journal.pone.0159717. eCollection 2016.

38.

Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis.

Ripoll È, de Ramon L, Draibe J, Merino A, Bolaños N, Goma M, Cruzado JM, Grinyó JM, Torras J.

Arthritis Res Ther. 2016 Jul 1;18(1):152. No abstract available.

39.

Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection.

Crespo E, Roedder S, Sigdel T, Hsieh SC, Luque S, Cruzado JM, Tran TQ, Grinyó JM, Sarwal MM, Bestard O.

Transplantation. 2017 Jun;101(6):1400-1409. doi: 10.1097/TP.0000000000001287.

PMID:
27362314
40.

JAK3-STAT pathway blocking benefits in experimental lupus nephritis.

Ripoll È, de Ramon L, Draibe Bordignon J, Merino A, Bolaños N, Goma M, Cruzado JM, Grinyó JM, Torras J.

Arthritis Res Ther. 2016 Jun 8;18(1):134. doi: 10.1186/s13075-016-1034-x. Erratum in: Arthritis Res Ther. 2016;18(1):152.

41.

Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.

Padullés A, Colom H, Bestard O, Melilli E, Sabé N, Rigo R, Niubó J, Torras J, Lladó L, Manito N, Caldés A, Cruzado JM, Grinyó JM, Lloberas N.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1992-2002. doi: 10.1128/AAC.02130-15. Print 2016 Apr.

42.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP.

N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med. 2016 Feb 18;374(7):698.

43.

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.

Rostaing L, Bunnapradist S, Grinyó JM, Ciechanowski K, Denny JE, Silva HT Jr, Budde K; Envarsus Study Group.

Am J Kidney Dis. 2016 Apr;67(4):648-59. doi: 10.1053/j.ajkd.2015.10.024. Epub 2015 Dec 22.

44.

A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.

Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gómez-Vaquero C, Polo C, Revuelta I, Francos J, Torras J, García-Barrasa A, Bestard O, Grinyó JM.

J Am Soc Nephrol. 2016 Aug;27(8):2487-94. doi: 10.1681/ASN.2015060622. Epub 2015 Dec 8.

45.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

46.

Clinical approach to kidney disease in kidney recipients in Spain.

Campistol JM, Gutiérrez-Dalmau A, Crespo J, Saval N, Grinyó JM; Grupo de Estudio Observa.

Nefrologia. 2015;35(3):256-63. doi: 10.1016/j.nefro.2015.05.006. Epub 2015 Jun 30. English, Spanish.

47.

Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.

Lúcia M, Luque S, Crespo E, Melilli E, Cruzado JM, Martorell J, Jarque M, Gil-Vernet S, Manonelles A, Grinyó JM, Bestard O.

Kidney Int. 2015 Oct;88(4):874-87. doi: 10.1038/ki.2015.205. Epub 2015 Jul 15.

PMID:
26176829
48.

De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring.

Melilli E, Crespo E, Sandoval D, Manonelles A, Sala N, Mast R, Padulles A, Grinyo JM, Bestard O, Cruzado JM.

Transpl Int. 2015 Nov;28(11):1283-90. doi: 10.1111/tri.12626. Epub 2015 Jul 14.

49.

Residual urinary volume is a risk factor for primary nonfunction in kidney transplantation.

Cruzado JM, Manonelles A, Vila H, Melilli E, Sala N, Bestard O, Torras J, Tebé C, Riera L, Grinyó JM.

Transpl Int. 2015 Nov;28(11):1276-82. doi: 10.1111/tri.12625. Epub 2015 Jul 6.

50.

CD154-CD40 T-cell co-stimulation pathway is a key mechanism in kidney ischemia-reperfusion injury.

de Ramon L, Ripoll E, Merino A, Lúcia M, Aran JM, Pérez-Rentero S, Lloberas N, Cruzado JM, Grinyó JM, Torras J.

Kidney Int. 2015 Sep;88(3):538-49. doi: 10.1038/ki.2015.146. Epub 2015 May 20.

Supplemental Content

Loading ...
Support Center